menu
    • menu
    [{"orgOrder":0,"company":"Kadimastem","sponsor":"iTolerance","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Kadimastem \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"Kadimastem \/ Kadimastem"},{"orgOrder":0,"company":"Kadimastem","sponsor":"iTolerance","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Kadimastem \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"Kadimastem \/ Kadimastem"},{"orgOrder":0,"company":"Kadimastem","sponsor":"iTolerance","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Kadimastem \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"Kadimastem \/ Kadimastem"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Bird Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"iTOL-102","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kadimastem \/ Bird Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kadimastem \/ Bird Foundation"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Embryonic Stem Cell","moa":"Pluripotency factors","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kadimastem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kadimastem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Undisclosed"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Kadimastem","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Kadimastem","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Kadimastem"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Nucelx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Merger","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Kadimastem","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Kadimastem"}]

    Find Clinical Drug Pipeline Developments & Deals by Kadimastem

    Menu

    Kadimastem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : Nucelx

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            NLS Pharmaceutics and Kadimastem Complete Merger

                            Details : The proposed merger involves AstroRx, a cell & gene therapy company, to advance treatments for central nervous system disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 30, 2025

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Nucelx

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : TargetGene Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NLS Pharmaceutics, Kadimastem Collaborate with TargetGene for Gene-Edited Cell Therapies

                            Details : The collaboration aims to advance AstroRx, a cell & gene therapy for central nervous system disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 27, 2025

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : TargetGene Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Bird Foundation

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BIRD Foundation Approves Milestone Payment for Type 1 Diabetes Cell Therapy

                            Details : The milestone is based on the progress in the development of iTOL-102, a novel cell therapy targeting a potential cure for Type 1 diabetes without the need for life-long immunosuppression.

                            Product Name : iTOL-102

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 17, 2025

                            Lead Product(s) : iTOL-102

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Bird Foundation

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery

                            Recipient : iTolerance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kadimastem, iTolerance Complete Pre-IND Meeting for Type 1 Diabetes Therapy

                            Details : iTOL-102 is developed using proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery

                            Recipient : iTolerance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : iTolerance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products...

                            Details : iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 07, 2023

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : iTolerance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : iTolerance

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Typ...

                            Details : Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : Allogenic Pancreatic Islet Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : iTolerance

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kadimastem Granted a Patent in Israel for the Treatment of ALS

                            Details : Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.

                            Product Name : AstroRx

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 09, 2021

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

                            Details : The primary objective of the trial was to evaluate the safety of AstroRx®, an "off-the-shelf", clinical-grade, astrocyte cell product, developed and manufactured by the Company. The trial met its endpoints.

                            Product Name : AstroRx

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 15, 2020

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

                            Details : Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

                            Product Name : AstroRx

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 03, 2020

                            Lead Product(s) : Human Pluripotent Stem Cell

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed

                            Kadimastem

                            Israel arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kadimastem reports positive ALS cell therapy results

                            Details : A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 02, 2020

                            Lead Product(s) : AstroRx

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth